GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Medlive Technology Co Ltd (HKSE:02192) » Definitions » Intrinsic Value: Projected FCF

Medlive Technology Co (HKSE:02192) Intrinsic Value: Projected FCF : HK$0.00 (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Medlive Technology Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-24), Medlive Technology Co's Intrinsic Value: Projected FCF is HK$0.00. The stock price of Medlive Technology Co is HK$7.63. Therefore, Medlive Technology Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Medlive Technology Co's Intrinsic Value: Projected FCF or its related term are showing as below:

HKSE:02192's Price-to-Projected-FCF is not ranked *
in the Medical Distribution industry.
Industry Median: 0.995
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Medlive Technology Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Medlive Technology Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medlive Technology Co Intrinsic Value: Projected FCF Chart

Medlive Technology Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Medlive Technology Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Medlive Technology Co's Intrinsic Value: Projected FCF

For the Medical Distribution subindustry, Medlive Technology Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medlive Technology Co's Price-to-Projected-FCF Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Medlive Technology Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Medlive Technology Co's Price-to-Projected-FCF falls into.



Medlive Technology Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Medlive Technology Co  (HKSE:02192) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Medlive Technology Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=7.63/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medlive Technology Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Medlive Technology Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Medlive Technology Co (HKSE:02192) Business Description

Traded in Other Exchanges
N/A
Address
No. 1 Baijialou Chaoyang North Road, E1 Red Manor International Bonded Innovation Park, Chaoyang District, Beijing, CHN
Medlive is a digital healthcare marketing company that produces customized content for pharmaceutical and medical device firms to specifically target physicians through different promotional channels. The company uses in-house and third-party content teams to produce advertising for its clients by profiling the user preferences of the physicians on the platform who drive procurement and prescription decisions. Its platform also provides medical content consisting of third-party research, informal discussions, and medical news articles. The company also operates a minor internet hospital and SaaS solution that help with medical conferences and clinical research. M3, Japan's leading digital healthcare marketing company owns 38.8% of Medlive through a joint venture.
Executives
Fil Limited 2201 Interest of corporation controlled by you
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
M3, Inc. 2101 Beneficial owner
Sony Group Corporation 2201 Interest of corporation controlled by you
Tian Liping
Zhang Xiaofeng 2101 Beneficial owner
Liu Lingdi 2101 Beneficial owner
Tian Lixin 2101 Beneficial owner
Brown Brothers Harriman & Co. 2502 Approved lending agent
Fidelity Funds 2101 Beneficial owner
Tiantian Co., Limited

Medlive Technology Co (HKSE:02192) Headlines

No Headlines